HOME >> MEDICINE >> NEWS
Trial opens new possibilities for improving survival with a novel heart attack drug

CHICAGO -- While the results of a new trial showed that a novel drug intended to reduce the extent of cell death after heart attack did not do so, the surprising finding that it reduced the death rate in patients who received angioplasties opens an intriguing new line of investigation, according to Duke University Medical Center researchers.

The drug, known as pexelizumab, was tested in a Phase II trial in conjunction with either clot-busting medications or angioplasty in acute heart attack patients to reduce the amount of tissue death, or infarct size, following treatment. The researchers, led by Duke cardiologists Christopher Granger, M.D., and Kenneth Mahaffey, M.D., found that while the infarct size remained the same in the treated and untreated groups, there was a greater than three times reduction (1.8 percent vs. 5.9 percent) in the death rate after 90 days in the patients who received the drug in conjunction with angioplasty.

"Unexpected findings like these can in many ways be the most exciting, because they open up whole new avenues of investigation," Granger said. He presented the results of the trial (Nov. 18, 2002) at the 75th annual scientific session of the American Heart Association.

"Although pexelizumab did not reduce the size of infarcts, the results may be pointing toward a novel mechanism that seems to benefit some patients with acute heart attacks," Granger continued. "This is quite exciting and worthy of further study."

In many ways, heart attack patients suffer twice. First, when blood flow is cut off to heart muscle during the attack, the resulting lack of oxygen kills or damages heart muscle cells. Then, after blood flow is restored, either by medication or angioplasty, the starved muscle cells are damaged again as a result of the sudden return of oxygen-rich blood, a condition known as reperfusion injury.

To date, no effective therapy has been discovered to reduce or stop the damage of reperfusion in
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
18-Nov-2002


Page: 1 2 3

Related medicine news :

1. Trial reveals safer and simpler approach to treating children with cystic fibrosis
2. Trials launched to test treatment of cognitive dysfunction in schizophrenia
3. Randomisation phase of the DIRECT programme (DIabetic REtinopathy Candesartan Trials) completed
4. Trials on hormone therapy and hypertension treatment change practice, medication usage of patients
5. Trial results have dramatically reduced HRT use
6. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
7. Clinical Trials Litigation: Legal & Ethical Issues in Human Subjects Research
8. National Lung Screening Trial
9. New awards, expanded focus for Pediatric AIDS Clinical Trials Group
10. AAPS Workshop to Examine Chemistry and Manufacturing Controls Trials, Emerging Products
11. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... ... In an effort to give back to the community in which it serves, ... with a special new rate code to benefit children and families at Ronald ... will be applied to any room type, any time, now through the end of ...
(Date:8/29/2020)... ... August 29, 2020 , ... When professor and author Randy Pausch was diagnosed ... people would. Rather than become melancholic, however, he put together a final lecture in ... Randy Pausch took a negative situation and turned it into something that inspired millions ...
(Date:8/28/2020)... FOOTHILL RANCH, Calif. (PRWEB) , ... August 28, ... ... NCPCV cover a one-year subscription to a customized Lighthouse Health & Wellness ... in generous support of this project. Motorola Solutions Foundation awards grants each year ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ziegler, a specialty investment ... investment in Synchronous Health, a tech-enabled behavioral health and well-being solutions provider. ... empathy with artificial intelligence (AI) to increase access and quality of behavioral health ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... is a leading aesthetic and wellness retreat. The practice is centered on results ... of Las Vegas. , Designed to be a sanctuary for total body ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... 03, 2020 , ... Q&J Face Masks announced today that ... and engineering lab, conducted tests on Q&J’s personal face mask that indicated the ... other masks. Q&J face masks have both mechanical filtering and electrostatic filtering which ...
(Date:9/3/2020)... ... September 03, 2020 , ... In response to the ... schools and classrooms across the United States, IntraLogic Solutions , a leading ... TEMPE is a non-contact, wall-mounted scanning thermometer that rapidly checks body temperatures. When ...
(Date:9/2/2020)... , ... September 02, 2020 ... ... Fight Against Covid-19 , Advanced Penetration Technology, LLC, (APT) a Texas- and ... patients utilizing non-prescription, Over The Counter (OTC) products, was today provided results ...
Breaking Medicine Technology:
Cached News: